Theradiag and its South Korean partners, Professor Chang-sik Yu and his team at Asan Medical Center and CbsBioscience will receive €1.3 million financial support from Eurostars program for its Pioneer collaborative project undertaken by its Prestizia molecular biology platform.
The purpose of the Pioneer project is to develop two tests based on circulating microRNA biomarkers and tissue messenger RNA (mRNA) in rectal cancer, which is a major health issue in Asian countries in particular, with the number of cases increasing by 5.9% per annum.
This €2.2 million 3-year project will help validate specific new markers via the recruitment of a cohort of more than 300 patients.